🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. Huperzine A, Huperzine A, Capsules, Huperzine A

    SUPERNUS PHARMACEUTICALS, INC.

    Focal Onset Seizures

    phase 2 small molecule active

    1 trial

  2. Hyaluronidase

    Amphastar France Pharmaceuticals

    Allergic Skin Reaction

    phase 2 small molecule completed

    1 trial

  3. Hydrocortisone acetate and lidocaine hydrochloride

    CITIUS ONCOLOGY, INC.

    Hemorrhoids

    phase 2 small molecule completed

    1 trial

  4. IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 125 mg hard capsules, Faslodex 250 mg solution for injection., JZP598

    Jazz Pharmaceuticals Ireland Limited

    Breast cancer patients including those with locally advanced (unresectable) or metastatic HER2-positive, HR-positive breast cancer

    phase 2 small molecule active

    1 trial

  5. IBUPROFEN , DEXAMETHASONE , FAMOTIDINE , SODIUM CHLORIDE , mRNA-3927, PARACETAMOL , CETIRIZINE

    Moderna Biotech Spain

    Propionic Acidemia

    phase 2 small molecule active

    1 trial

  6. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. ICP-022

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  8. IDARUBICIN, FLUDARABINE, CYTARABINE, DAUNORUBICIN, MITOXANTRONE, ETOPOSIDE, PKC412

    Novartis Pharmaceuticals

    untreated FLT3-mutated Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  9. IDOR-1117-2520 matching placebo

    Lacuna Pharma Pty Ltd

    Moderate to severe chronic plaque psoriasis

    phase 2 small molecule active

    1 trial

  10. IL-1Ra Kineret®

    United Therapeutics Europe Ltd

    Intracerebral Haemorrhage

    phase 2 small molecule completed

    1 trial

  11. ILT-101 liquide, Placebo of ILT-101

    Pari Pharma GmbH

    Autism Spectrum disorder ASD

    phase 2 small molecule active

    1 trial

  12. ILT-101 liquide, Placebo of ILT-101, CICLOSPORIN

    Pari Pharma GmbH

    Patient with newly diagnosed (≤ 3 months) type 1 diabetes stage 3

    phase 2 small molecule active

    1 trial

  13. INAVOLISIB, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, Inavolisib placebo, FULVESTRANT

    Hoffmann-La Roche

    Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation

    phase 2 small molecule active

    1 trial

  14. INC280

    Novartis Pharmaceuticals

    Non-small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  15. INCB000928, Placebo

    Incyte

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule active

    1 trial

  16. INM-755 (cannabinol) cream

    InMed Pharmaceuticals

    Epidermolysis Bullosa Simplex

    phase 2 small molecule completed

    1 trial

  17. INO-3107

    INOVIO PHARMACEUTICALS, INC.

    Respiratory Papillomatosis

    phase 2 small molecule completed

    1 trial

  18. INO-3112

    INOVIO PHARMACEUTICALS, INC.

    Cervical Cancer

    phase 2 mab completed

    1 trial

  19. INO-3112

    INOVIO PHARMACEUTICALS, INC.

    Head and Neck Squamous Cell Cancer

    phase 2 mab completed

    1 trial

  20. INO-3112 vaccine

    INOVIO PHARMACEUTICALS, INC.

    Uterine Cervical Neoplasms

    phase 2 mab terminated

    1 trial

  21. INO-4700

    INOVIO PHARMACEUTICALS, INC.

    Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

    phase 2 small molecule completed

    1 trial

  22. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    Glioblastoma

    phase 2 mab active

    1 trial

  23. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    Urothelial Carcinoma

    phase 2 mab completed

    1 trial

  24. IOHEXOL , Placebo to match LY3437943, Retatrutide

    Eli Lilly Co.

    Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources